FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1640-1641 November 30, 2000 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article Related Article by Bathon, J. M. Related Article by Lipsky, P. E. PubMed Citation

This year marks the 50th anniversary of the awarding of the Nobel Prize in Physiology and Medicine to Kendall, Hench, and Reichstein for the isolation and characterization of adrenocorticotrophic hormones.¹ Until now, nothing has even begun to approach the dramatic effect glucocorticoids have had in improving the care of patients with rheumatoid arthritis and other systemic inflammatory diseases and creating optimism in the arthritis community. Products devised by the biotechnology industry for the treatment of rheumatoid arthritis have now been introduced into the clinic and appear to have ushered in a new era of scientifically based therapy for arthritis. Products . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Vidal, F., Fontova, R., Richart, C. (2003). Severe Neutropenia and Thrombocytopenia Associated with Infliximab. ANN INTERN MED 139: W-63-W-63 [Full Text]  
• Long, R., Gardam, M. (2003). Tumour necrosis factor-{alpha} inhibitors and the reactivation of latent tuberculosis infection. CMAJ 168: 1153-1156 [Full Text]  
• Breban, M., Vignon, E., Claudepierre, P., Devauchelle, V., Wendling, D., Lespessailles, E., Euller-Ziegler, L., Sibilia, J., Perdriger, A., Mezieres, M., Alexandre, C., Dougados, M. (2002). Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) 41: 1280-1285 [Abstract] [Full Text]  
• Newhouse, J. P. (2002). Why Is There A Quality Chasm?. Health Aff (Millwood) 21: 13-25 [Abstract] [Full Text]  
• de Boer, W. I. (2002). Cytokines and Therapy in COPD* : A Promising Combination?. Chest 121 : 209S-218S [Abstract] [Full Text]  
• Burt, R. K., Slavin, S., Burns, W. H., Marmont, A. M. (2002). Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?. Blood 99: 768-784 [Abstract] [Full Text]  
• Rovere Querini, P., Vecellio, M., Sabbadini, M. G., Ciboddo, G. (2002). Miliary tuberculosis after biological therapy for rheumatoid arthritis. Rheumatology (Oxford) 41: 231-231 [Full Text]  
• Kraetsch, H G, Antoni, C, Kalden, J R, Manger, B (2001). Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis 60: iii55-57 [Abstract] [Full Text]  
• (2001). Robin Goodfellow. Rheumatology (Oxford) 40: 479-479 [Full Text]  
• (2000). TNF Inhibitors for Rheumatoid Arthritis. JWatch General 2000: 1-1 [Full Text]